Pharma Blog Watch

Acuity's Wet AMD Treatment Trial (The Pharm Voice)
In her blog, Gloria Gamat reports on recently announced results from Acuity Pharma's Phase II study of bevasiranib sodium, a compound being developed to treat wet age-related macular degeneration (AMD) that "works by shutting down the genes that produce [vascular endothelial growth factor]."